Acute myeloid leukemia (AML)‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in AML through IL‐6/JAK2/STAT3 signaling
Authors:
Open Access
- 4 June 2023
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 114 (8) , 3287-3300
Abstract
Acute myeloid leukemia (AML) has a high rate of treatment failure due to increased prevalence of therapy resistance. Mesenchymal stem cells (MSCs) in the leukemia microenvironment contribute to chemoresistance in AML, but the specific mechanism remains unclear. The critical role of the epithelial–mesenchymal transition (EMT)‐like profile in AML chemoresistance has been gradually recognized. However, there is no research to suggest that the AML‐derived bone marrow mesenchymal stem cells (AML‐MSCs) induce the EMT program in AML thus far. We isolated AML‐MSCs and cocultured them with AML cells. We found that AML‐MSCs induced a significant mesenchymal‐like morphology in drug‐resistant AML cells, but it was scarce in parental AML cells. The AML‐MSCs promoted growth of AML cells in the presence or absence of chemotherapeutics in vitro and in vivo. Acute myeloid leukemia MSCs also induced EMT marker expression in AML cells, especially in chemoresistant AML cells. Mechanistically, AML‐MSCs secreted abundant interleukin‐6 (IL‐6) and upregulated IL‐6 expression in AML cells. Acute myeloid leukemia cells upregulated IL‐6 expression in AML‐MSCs in turn. Meanwhile, AML‐MSCs activated the JAK2/STAT3 pathway in AML cells. Two JAK/STAT pathway inhibitors counteracted the AML‐MSCs induced morphology change and EMT marker expression in AML cells. In conclusion, AML‐MSCs not only promote the emergence of chemoresistance but also enhance it once AML acquires chemoresistance. AML‐MSCs induce EMT‐like features in AML cells; this phenotypic change could be related to chemoresistance progression. AML‐MSCs induce the EMT‐like program in AML cells through IL‐6/JAK2/STAT3 signaling, which provides a therapeutic target to reverse chemoresistance in AML.Keywords
This publication has 48 references indexed in Scilit:
- Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemiaJournal of Translational Medicine, 2018
- Emerging roles of epithelial-mesenchymal transition in hematological malignanciesJournal of Biomedical Science, 2018
- Tumor‑derived mesenchymal‑stem‑cell‑secreted IL‑6 enhances resistance to cisplatin via the STAT3 pathway in breast cancerOncology Letters, 2018
- Targeting the IL-6/JAK/STAT3 signalling axis in cancerNature Reviews Clinical Oncology, 2018
- Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signalingCell Death & Disease, 2018
- EMT‐ and MET‐related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunitiesMolecular Oncology, 2017
- De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changesScientific Reports, 2017
- Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic ImplicationsStem Cells International, 2017
- Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?Stem Cells, 2010
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006